Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have received an average recommendation of “Hold” from the five analysts that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $3.33.

SYRS has been the topic of a number of analyst reports. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday. They set a “sell” rating on the stock. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th.

Insiders Place Their Bets

In other news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now owns 41,070 shares of the company’s stock, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 12.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals during the 3rd quarter worth $34,000. Two Sigma Securities LLC purchased a new stake in Syros Pharmaceuticals during the 4th quarter worth $25,000. Finally, Exome Asset Management LLC increased its stake in Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares during the period. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Stock Performance

Shares of NASDAQ SYRS opened at $0.18 on Friday. Syros Pharmaceuticals has a 1 year low of $0.16 and a 1 year high of $7.96. The firm’s 50 day moving average price is $0.20 and its 200 day moving average price is $1.23. The firm has a market cap of $4.72 million, a P/E ratio of -0.06 and a beta of 1.29.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.